Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

City Of Hope Certified to Provide First FDA-Approved Car T-Cell Therapy For Pediatric And Young Adult Patients With Relapsed/Refractory B-Cell ALL

Published: Monday, Apr 23, 2018

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy—the first CAR T cell therapy approved by the FDA—to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

City of Hope is the only institution in Southern California to currently offer both tisagenlecleucel and axicabtagene ciloleucel (commercial name Yescarta), the second CAR T cell therapy approved by the FDA, solidifying City of Hope’s position as a leader in this newest form of cancer immunotherapy.

Tisagenlecleucel, a Novartis product, is a CAR T therapy and one-time treatment that uses a patient's own T cells to fight B cell precursor ALL that has resisted all treatment options or has relapsed a second or subsequent time.

“CAR T therapy is a lifesaver for people living with certain cancers that are difficult to treat, and City of Hope is proud to be at the forefront of advancing this innovative approach,” said Joseph Rosenthal, M.D., Barron Hilton Chair in Pediatrics and chair of City of Hope's Department of Pediatrics. “With tisagenlecleucel, we now have the opportunity to provide this novel cell-based therapy to our youngest ALL patients who are in need of other treatment options.”

CAR T Expertise at City of Hope

City of Hope is a recognized leader in the advancement of CAR T cell therapies. City of Hope applies its proprietary CAR T cell technology in active preclinical and clinical programs across a range of hematologic cancers and solid tumors, and collaborates with other academic researchers and global biopharmaceutical companies to advance clinical research in areas of high unmet medical need and make their therapies available to patients.

City of Hope’s Department of Pediatrics has a long history dating back to the early 1960s. In addition to offering Kymriah to eligible pediatric patients, City of Hope also offers CAR T clinical trials to patients with ALL ages 18 and up, and patients ages 12 and up with acute myeloid leukemia and glioblastoma.

In addition, City of Hope’s history with CAR T cell therapy dates back to the late 1990s. Since then, more than 180 patients have been treated in CAR T trials at City of Hope; the institution was also the first to administer CAR T cell therapy locally in the brain to glioblastoma patients through direct injection to the tumor site and/or through infusion in the ventricular system.

City of Hope was also the first to offer CAR T trials targeting CD123 in acute myeloid leukemia. City of Hope, which has one of the most comprehensive CAR T cell clinical research programs in the world, currently has 14 ongoing CAR T clinical trials and plans to open additional trials in 2018 for patients with a variety of cancer types, including HER2 positive breast cancer with brain metastatic disease. City of Hope’s unique blend of multidisciplinary specialization – encompassing physicians, nurses and intensive care and transfusion medicine experts sharing stem cell transplant expertise – will also benefit CAR T patients, who require intensive medical care after treatment.

Patients interested in learning more about tisagenlecleucel treatment at City of Hope can call 833-310-CART(2278) or visit CityofHope.org/ALL-CAR-T.

About City of Hope

City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world.

City of Hope's main campus is in Duarte, California, just northeast of Los Angeles, with additional locations throughout Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution.

For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x